Vanguard Group Updates 9.4% Stake in Arrowhead Pharma

TL;DR

**Vanguard still owns 9.4% of Arrowhead Pharma, slightly down but still a big holder.**

AI Summary

The Vanguard Group, a major investment management company, filed an amended SC 13G/A on February 13, 2024, disclosing its ownership in Arrowhead Pharmaceuticals Inc. As of December 29, 2023, Vanguard holds 10,076,094 shares of Arrowhead's Common Stock, representing 9.4% of the company's total outstanding shares. This filing indicates a slight decrease in Vanguard's percentage ownership from its previous disclosure, which is important for investors as it shows a large institutional investor's updated position in the company.

Why It Matters

This filing shows that a major institutional investor, The Vanguard Group, continues to hold a significant stake in Arrowhead Pharmaceuticals, signaling ongoing confidence, albeit with a slight reduction in percentage ownership.

Risk Assessment

Risk Level: low — This filing is routine for large institutional investors and does not indicate any immediate significant risk or opportunity, but rather an update to their holdings.

Analyst Insight

Investors should note Vanguard's continued significant, though slightly reduced, stake as a sign of ongoing institutional interest in Arrowhead Pharmaceuticals, but should not interpret it as a strong buy or sell signal without further analysis.

Key Numbers

• 10,076,094 — Shares Owned (The total number of Common Stock shares of Arrowhead Pharmaceuticals Inc. beneficially owned by The Vanguard Group as of December 29, 2023.)
• 9.4% — Percentage of Class (The percentage of Arrowhead Pharmaceuticals Inc.'s Common Stock class beneficially owned by The Vanguard Group as of December 29, 2023.)

Key Players & Entities

• The Vanguard Group (company) — reporting person and institutional investor
• Arrowhead Pharmaceuticals Inc. (company) — issuer of the securities
• 10,076,094 (dollar_amount) — number of shares beneficially owned by Vanguard
• 9.4% (dollar_amount) — percentage of class owned by Vanguard
• December 29, 2023 (date) — date of event requiring the filing
• February 13, 2024 (date) — filing date of the SC 13G/A

Forward-Looking Statements

• Vanguard will maintain a significant, but potentially slightly adjusted, stake in Arrowhead Pharmaceuticals over the next year. (The Vanguard Group) — high confidence, target: 2025-02-13

FAQ

Filing Documents

• tv0336-arrowheadpharmaceutic.htm (SC 13G/A) — 11KB
• 0001104659-24-020333.txt ( ) — 13KB

(a) - Name of Issuer

Item 1(a) - Name of Issuer: Arrowhead Pharmaceuticals Inc

(b) - Address of Issuer's Principal Executive Offices

Item 1(b) - Address of Issuer's Principal Executive Offices: 177 East Colorado Boulevard, Suite 700 Pasadena, CA 91105

(a) - Name of Person Filing

Item 2(a) - Name of Person Filing: The Vanguard Group - 23-1945930

(b) – Address of Principal Business Office or, if none, residence

Item 2(b) – Address of Principal Business Office or, if none, residence: 100 Vanguard Blvd. Malvern, PA 19355

(c) – Citizenship

Item 2(c) – Citizenship: Pennsylvania

(d) - Title of Class of Securities

Item 2(d) - Title of Class of Securities: Common Stock

(e) - CUSIP Number

Item 2(e) - CUSIP Number 04280A100

- Type of Filing

Item 3 - Type of Filing: This statement is being filed pursuant to Rule 13d-1. An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E).

- Ownership

Item 4 - Ownership: (a) Amount Beneficially Owned: (b) Percent of Class: (c) Number of shares as to which such person has: (i) sole power to vote or direct to vote: (ii) shared power to vote or direct to vote: (iii) sole power to dispose of or to direct the disposition of: (iv) shared power to dispose or to direct the disposition of: Comments: The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.

- Ownership of Five Percent or Less of a Class

Item 5 - Ownership of Five Percent or Less of a Class: If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following

- Ownership of More Than Five Percent on Behalf of Another Person

Item 6 - Ownership of More Than Five Percent on Behalf of Another Person: The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein. No one other person's interest in the securities reported herein is more than 5%. Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company: Not applicable

- Identification and Classification of Members of Group

Item 8 - Identification and Classification of Members of Group: Not applicable

- Notice of Dissolution of Group

Item 9 - Notice of Dissolution of Group: Not applicable

- Certification

Item 10 - Certification: By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: February 13, 2024 By /s/ Ashley Grim Name: Ashley Grim Title: Head of Global Fund Administration

View Full Filing

View this SC 13G/A filing on SEC EDGAR